» Articles » PMID: 38202257

Pathogenic Variant Frequencies in Hereditary Haemorrhagic Telangiectasia Support Clinical Evidence of Protection from Myocardial Infarction

Overview
Journal J Clin Med
Specialty General Medicine
Date 2024 Jan 11
PMID 38202257
Authors
Affiliations
Soon will be listed here.
Abstract

Hereditary haemorrhagic telangiectasia (HHT) is a vascular dysplasia inherited as an autosomal dominant trait, due to a single heterozygous loss-of-function variant, usually in (encoding activin receptor-like kinase 1 [ALK1]), (encoding endoglin [CD105]), or . In a consecutive single-centre series of 37 positive clinical genetic tests performed in 2021-2023, a skewed distribution pattern was noted, with 30 of 32 variants reported only once, but c.1231C>T (p.Arg411Trp) identified as the disease-causal gene in five different HHT families. In the same centre's non-overlapping 1992-2020 series where 110/134 (82.1%) HHT-causal variants were reported only once, c.1231C>T (p.Arg411Trp) was identified in nine further families. In a 14-country, four-continent HHT Mutation Database where 181/250 (72.4%) HHT-causal variants were reported only once, c.1231C>T (p.Arg411Trp) was reported by 12 different laboratories, the adjacent c.1232G>A (p.Arg411Gln) by 14, and c.1120C>T (p.Arg374Trp) by 18. Unlike the majority of HHT-causal variants, these encode ALK1 protein that reaches the endothelial cell surface but fails to signal. Six variants of this type were present in the three series and were reported 6.8-25.5 (mean 8.9) times more frequently than the other missense variants (all -values < 0.0039). Noting lower rates of myocardial infarction reported in HHT, we explore potential mechanisms, including a selective paradigm relevant to ALK1's role in the initiating event of atherosclerosis, where a plausible dominant negative effect of these specific variants can be proposed. In conclusion, there is an ~9-fold excess of kinase-inactive, cell surface-expressed /ALK1 pathogenic missense variants in HHT. The findings support further examination of differential clinical and cellular phenotypes by HHT causal gene molecular subtypes.

Citing Articles

Hereditary haemorrhagic telangiectasia.

Hermann R, Shovlin C, Kasthuri R, Serra M, Eker O, Bailly S Nat Rev Dis Primers. 2025; 11(1):1.

PMID: 39788978 DOI: 10.1038/s41572-024-00585-z.


When "loss-of-function" means proteostasis burden: Thinking again about coding DNA variants.

Shovlin C, Aldred M Am J Hum Genet. 2025; 112(1):3-10.

PMID: 39753117 PMC: 11739917. DOI: 10.1016/j.ajhg.2024.12.002.


The double whammy of ER-retention and dominant-negative effects in numerous autosomal dominant diseases: significance in disease mechanisms and therapy.

Gariballa N, Mohamed F, Badawi S, Ali B J Biomed Sci. 2024; 31(1):64.

PMID: 38937821 PMC: 11210014. DOI: 10.1186/s12929-024-01054-1.


Mutations causing premature termination codons discriminate and generate cellular and clinical variability in HHT.

Bernabeu-Herrero M, Patel D, Bielowka A, Zhu J, Jain K, Mackay I Blood. 2024; 143(22):2314-2331.

PMID: 38457357 PMC: 11181359. DOI: 10.1182/blood.2023021777.

References
1.
Sharma L, Almaghlouth F, Mckernan H, Springett J, Tighe H, Shovlin C . Iron deficiency responses and integrated compensations in patients according to hereditary hemorrhagic telangiectasia and genotypes. Haematologica. 2023; 109(3):958-962. PMC: 10905072. DOI: 10.3324/haematol.2022.282038. View

2.
Trembath R, Thomson J, Machado R, Morgan N, Atkinson C, Winship I . Clinical and molecular genetic features of pulmonary hypertension in patients with hereditary hemorrhagic telangiectasia. N Engl J Med. 2001; 345(5):325-34. DOI: 10.1056/NEJM200108023450503. View

3.
Major T, Bereczky Z, Gindele R, Balogh G, Racz B, Bora L . Current Status of Clinical and Genetic Screening of Hereditary Hemorrhagic Telangiectasia Families in Hungary. J Clin Med. 2021; 10(17). PMC: 8432115. DOI: 10.3390/jcm10173774. View

4.
Forrest A, Kawaji H, Rehli M, Baillie J, de Hoon M, Haberle V . A promoter-level mammalian expression atlas. Nature. 2014; 507(7493):462-70. PMC: 4529748. DOI: 10.1038/nature13182. View

5.
Shovlin C, Patel D, Bielowka A, Ledermann J, Modarresi A, Bernabeu-Herrero M . MEK 1 inhibition and bleeding in hereditary haemorrhagic telangiectasia. Br J Haematol. 2023; 204(1):361-365. DOI: 10.1111/bjh.19167. View